The polymerase chain reaction (PCR) and viral culture techniques were prospectively compared for the detection of cytomegalovirus (CMV) in blood samples from 24 liver transplant recipients. Nine patients had one or more episodes of viremia, seven of which were clinically symptomatic infections. All samples in which CMV was isolated by culture were positive by the PCR. However, the PCR result was also positive for one ture and fever, malaise, and usually leukothrombocytopenia) or histological evidence of tissue invasion by CMV or both.
Cytomegalovirus (CMV) is the single most frequent infectious agent in liver transplantation (11) . In transplantation patients, CMV not only is a major cause of morbidity and mortality but also can be associated with an immunosuppressive state, superinfection by other opportunistic microorganisms, and allograft rejection (7) . Viremia is a prominent feature of CMV infection and, unlike urinary or pharyngeal shedding, is frequently associated with clinical symptoms and organ involvement (6, 11) . Therefore, an early and sensitive diagnosis of CMV viremia may be of clinical importance in that it may trigger a search for organ invasion and potential early antiviral therapy. Of ture and fever, malaise, and usually leukothrombocytopenia) or histological evidence of tissue invasion by CMV or both.
Twenty-four liver transplant patients were studied, with a mean follow-up of 81 days (range, 35 to 180 days). Blood samples for culture and the PCR were obtained on days 0, 7, 14, 21, 28, 60, 120, and 180 posttransplantation and for any suspicious episode of CMV infection. A pharyngeal swab and urine samples were also simultaneously cultured for CMV. Donor and recipient pretransplant serum samples were tested for anti-CMV immunoglobulin G by a commercial enzyme immunoassay (Sigma, St. Louis, Mo.). Conventional viral culture and rapid culture by the shell vial technique were performed as previously described (9) . For the PCR reactions, 7.5 x 104 leukocytes were lysed at 56°C for 60 min in 10 mM Tris-HCl (pH 8.3)-50 mM KCl-2.5 mM MgCl2-0.15% Nonidet P-40 and Tween 20-60 ,ug of proteinase K per ml. After heat inactivation, DNA amplification of a region of CMV IEl gene was performed with 0.5 ,uM of specific primers (4) and 1.25 U of Taq polymerase (PerkinElmer, Norwalk, Conn.) in the same buffer described above at a final MgCl2 concentration of 1.5 mM. The samples were then heated at 95°C for 1 min and subjected to 35 cycles at 95°C for 1 min and at 60°C for 1 min, with a final extension segment at 60°C for 10 min. Ten microliters of the resulting product (50 ,ul) was electrophoresed in 4% agarose (NuSieve, 3%; SeaKem, 1%; FMC), stained, and photographed. The total processing time was 7 h. Human fibroblasts infected with CMV AD169 and leukocytes from CMVseropositive and -seronegative healthy blood donors were used as controls. The minimal level of CMV DNA in our samples detected by the PCR, with the linearized cosmid pCM1058 containing the HindIII E fragment of AD169 (2), was in the range of 102 to 103 DNA copies.
One hundred forty-five blood samples from 24 patients were tested. The results are summarized in Table 1 . CMV was cultured in 11 blood leukocyte samples from nine patients. All samples in which CMV was cultured were positive by the PCR. CMV DNA was also detected by the PCR in 32 blood leukocyte samples from nine patients without viremia. None of the CMV-seropositive and -sero- negative blood donor controls (n = 25) had a positive result by the PCR. For all the samples from the transplantation patients, the sensitivity of the PCR with respect to that of the culture technique was 100%, with a specificity of 76% and a positive predictive value of 25.5%. After transplant, the mean time for the first positive blood leukocyte culture was 52 days (range, 28 to 84 days), while the mean time for the first positive PCR result was 30 days (range, 7 to 70 days). For four patients, CMV DNA was detected by the PCR before viral isolation, while in the remaining five viremic patients, the PCR and viral culture results were simultaneously positive. No specific differences, such as time of detection, donor and recipient pretransplant serology, culture of CMV from other locations, and antirejection therapy (OKT3) (data not shown), could be found between the PCR-positive-culture-negative patients and the PCR-negative-culture-negative patients. We also evaluated the use of the PCR for the group of patients at highest risk for symptomatic CMV infection (CMV-seronegative recipients of CMV-seropositive donors). Two of the four patients in this group developed severe CMV disease. All four patients had positive PCR results. Two of them had positive PCR results as early as 7 days posttransplant, at which time the viral culture was negative.
The seven patients in our study who had clinical symptoms related to CMV infection were treated with ganciclovir. For five of these patients, the PCR result was persistently positive (range, 7 to 56 days) after the beginning of antiviral treatment, at which time viral cultures were negative. The clinical importance of this finding remains to be evaluated.
Our results suggest that the PCR may not be a useful method for the diagnosis of CMV disease: of the 18 patients with a positive PCR result, 11 never developed symptomatic infection, whereas 7 of the 9 viremic patients were symptomatic. Therefore, culture of CMV from blood leukocytes is a better marker than the PCR for symptomatic infection associated with organ invasion. Seven of the nine patients with positive PCR results and negative blood leukocyte cultures had evidence of CMV infection at other sites in an asymptomatic form, indicating that it is unlikely that these PCR results were false positive.
In conclusion, our study showed that even though the PCR of CMV DNA may be a very sensitive technique for CMV viremia detection, it is not useful as a marker of clinically symptomatic CMV infection, as a large number of the PCR-positive patients never developed clinical disease. Our data are in accord with those of Gerna et al. (3) 
